Logo image of IMVT

IMMUNOVANT INC (IMVT) Stock Fundamental Analysis

USA - NASDAQ:IMVT - US45258J1025 - Common Stock

17.03 USD
-0.45 (-2.57%)
Last: 10/10/2025, 9:35:47 PM
16.95 USD
-0.08 (-0.47%)
After Hours: 10/10/2025, 9:35:47 PM
Fundamental Rating

3

Taking everything into account, IMVT scores 3 out of 10 in our fundamental rating. IMVT was compared to 537 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMVT as it has an excellent financial health rating, but there are worries on the profitability. IMVT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMVT has reported negative net income.
In the past year IMVT has reported a negative cash flow from operations.
In the past 5 years IMVT always reported negative net income.
IMVT had a negative operating cash flow in each of the past 5 years.
IMVT Yearly Net Income VS EBIT VS OCF VS FCFIMVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

IMVT has a worse Return On Assets (-67.63%) than 61.19% of its industry peers.
IMVT has a Return On Equity (-73.50%) which is in line with its industry peers.
Industry RankSector Rank
ROA -67.63%
ROE -73.5%
ROIC N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
IMVT Yearly ROA, ROE, ROICIMVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMVT Yearly Profit, Operating, Gross MarginsIMVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for IMVT has been increased compared to 1 year ago.
IMVT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMVT Yearly Shares OutstandingIMVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
IMVT Yearly Total Debt VS Total AssetsIMVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

An Altman-Z score of 30.42 indicates that IMVT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 30.42, IMVT belongs to the best of the industry, outperforming 94.59% of the companies in the same industry.
There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 30.42
ROIC/WACCN/A
WACCN/A
IMVT Yearly LT Debt VS Equity VS FCFIMVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 12.32 indicates that IMVT has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.32, IMVT belongs to the best of the industry, outperforming 85.07% of the companies in the same industry.
IMVT has a Quick Ratio of 12.32. This indicates that IMVT is financially healthy and has no problem in meeting its short term obligations.
IMVT's Quick ratio of 12.32 is amongst the best of the industry. IMVT outperforms 85.07% of its industry peers.
Industry RankSector Rank
Current Ratio 12.32
Quick Ratio 12.32
IMVT Yearly Current Assets VS Current LiabilitesIMVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IMVT have decreased strongly by -47.67% in the last year.
EPS 1Y (TTM)-47.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IMVT will show a very strong growth in Earnings Per Share. The EPS will grow by 27.83% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.94%
EPS Next 2Y-4.65%
EPS Next 3Y0.85%
EPS Next 5Y27.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMVT Yearly Revenue VS EstimatesIMVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
IMVT Yearly EPS VS EstimatesIMVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMVT Price Earnings VS Forward Price EarningsIMVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMVT Per share dataIMVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.65%
EPS Next 3Y0.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOVANT INC

NASDAQ:IMVT (10/10/2025, 9:35:47 PM)

After market: 16.95 -0.08 (-0.47%)

17.03

-0.45 (-2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)10-31 2025-10-31
Inst Owners54.43%
Inst Owner Change0%
Ins Owners1.57%
Ins Owner Change0.18%
Market Cap2.97B
Analysts82.73
Price Target40.46 (137.58%)
Short Float %22.32%
Short Ratio10.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.22%
Min EPS beat(2)-7.99%
Max EPS beat(2)12.44%
EPS beat(4)2
Avg EPS beat(4)-4.13%
Min EPS beat(4)-21.51%
Max EPS beat(4)12.44%
EPS beat(8)4
Avg EPS beat(8)-2.89%
EPS beat(12)4
Avg EPS beat(12)-6.68%
EPS beat(16)5
Avg EPS beat(16)-6.51%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.33%
EPS NQ rev (1m)0.8%
EPS NQ rev (3m)1.03%
EPS NY rev (1m)-0.92%
EPS NY rev (3m)-2.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.88
P/tB 4.88
EV/EBITDA N/A
EPS(TTM)-2.85
EYN/A
EPS(NY)-3
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS0
BVpS3.49
TBVpS3.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.63%
ROE -73.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 142.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.32
Quick Ratio 12.32
Altman-Z 30.42
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)154.15%
Cap/Depr(5y)190.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.33%
EPS Next Y-9.94%
EPS Next 2Y-4.65%
EPS Next 3Y0.85%
EPS Next 5Y27.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.41%
EBIT Next 3Y1.27%
EBIT Next 5YN/A
FCF growth 1Y-145.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-145.72%
OCF growth 3YN/A
OCF growth 5YN/A